VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.9%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
11.98%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| 1 |
DT Midstream
DTM
|
$1.86M |
| 2 |
ScottsMiracle-Gro
SMG
|
$878K |
| 3 |
Valero Energy
VLO
|
$790K |
| 4 |
FMC
FMC
|
$775K |
| 5 |
Delek US
DK
|
$761K |
Top Sells
| 1 |
COR
Coresite Realty Corporation
COR
|
$1.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
$551K |
| 4 |
Travere Therapeutics
TVTX
|
$479K |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$448K |
Sector Composition
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Immunovant
IMVT
$2.81B
| $191K | 0.07% |
22,435
+2,641
| +13% | +$22.5K |
|
227
MeiraGTx Holdings
MGTX
$621M
| $191K | 0.07% |
8,032
-5,975
| -43% | -$142K |
|
228
Erasca
ERAS
$420M
| $190K | 0.07% |
+12,213
| New | +$190K |
|
|
KRTX
229
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $190K | 0.07% |
1,451
-193
| -12% | -$25.3K |
|
|
ISEE
230
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $190K | 0.07% |
11,360
-22,931
| -67% | -$384K |
|
231
Immunocore
IMCR
$1.78B
| $189K | 0.07% |
5,523
+164
| +3% | +$5.61K |
|
232
Protagonist Therapeutics
PTGX
$3.71B
| $189K | 0.07% |
5,521
+351
| +7% | +$12K |
|
|
MRNS
233
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $189K | 0.07% |
15,932
+4,597
| +41% | +$54.5K |
|
234
Mirum Pharmaceuticals
MIRM
$3.73B
| $188K | 0.07% |
11,817
-167
| -1% | -$2.66K |
|
235
Kura Oncology
KURA
$706M
| $187K | 0.07% |
13,354
+4,263
| +47% | +$59.7K |
|
236
Mersana Therapeutics
MRSN
$35.5M
| $186K | 0.07% |
1,199
+632
| +111% | +$98K |
|
237
Merus
MRUS
$5.01B
| $186K | 0.07% |
5,843
-3,548
| -38% | -$113K |
|
|
GRTS
238
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $184K | 0.07% |
14,346
-6,491
| -31% | -$83.3K |
|
239
Atea Pharmaceuticals
AVIR
$264M
| $183K | 0.07% |
20,481
+11,549
| +129% | +$103K |
|
240
MEI Pharma
MEIP
$140M
| $183K | 0.07% |
3,422
+181
| +6% | +$9.68K |
|
241
Quince Therapeutics
QNCX
$85.9M
| $183K | 0.07% |
14,471
+9,997
| +223% | +$126K |
|
|
INBX
242
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $183K | 0.07% |
4,200
-4,495
| -52% | -$196K |
|
243
AnaptysBio
ANAB
$590M
| $182K | 0.07% |
5,235
-3,302
| -39% | -$115K |
|
|
KDNY
244
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $182K | 0.07% |
11,158
-1,474
| -12% | -$24K |
|
245
Relay Therapeutics
RLAY
$690M
| $181K | 0.07% |
5,885
-328
| -5% | -$10.1K |
|
246
C4 Therapeutics
CCCC
$190M
| $180K | 0.07% |
5,589
+546
| +11% | +$17.6K |
|
247
Gossamer Bio
GOSS
$571M
| $180K | 0.07% |
15,932
-8,178
| -34% | -$92.4K |
|
248
IDEAYA Biosciences
IDYA
$2.26B
| $180K | 0.07% |
7,622
-2,053
| -21% | -$48.5K |
|
249
4D Molecular Therapeutics
FDMT
$309M
| $179K | 0.07% |
8,140
+883
| +12% | +$19.4K |
|
250
Phathom Pharmaceuticals
PHAT
$851M
| $179K | 0.07% |
9,080
+2,930
| +48% | +$57.8K |
|